MAM
EIGR

Meeder Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Meeder Asset Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-54
Closed -$11K – 2566
2020
Q1 		$11K Buy
54
+25
+86% +$7.97K ﹤0.01% 1494
2019
Q4 		$13K Buy
29
+9
+45% +$3.19K ﹤0.01% 1495
2019
Q3 		$6K Hold
20
– – ﹤0.01% 1723
2019
Q2 		$6K Hold
20
– – ﹤0.01% 1628
2019
Q1 		$8K Sell
20
-10
-33% -$4.01K ﹤0.01% 1306
2018
Q4 		$9K Hold
30
– – ﹤0.01% 1286
2018
Q3 		$11K Buy
30
+23
+329% +$7.87K ﹤0.01% 1146
2018
Q2 		$2.49K Sell
7
-9
-56% -$3.21K ﹤0.01% 1390
2018
Q1 		$5K Sell
16
-1
-6% -$295 ﹤0.01% 1244
2017
Q4 		$7K Sell
17
-6
-26% -$2.14K ﹤0.01% 1236
2017
Q3 		$7K Buy
23
+7
+44% +$1.91K ﹤0.01% 1174
2017
Q2 		$4K Hold
16
– – ﹤0.01% 1284
2017
Q1 		$5K Sell
16
-3
-16% -$1.03K ﹤0.01% 1106
2016
Q4 		$7K Buy
+19
New +$6.96K ﹤0.01% 819

Other funds holding EIGR

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Meeder Asset Management's EIGR Position: Q2 2020 in Review

Meeder Asset Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2020, closing a stake of 54 shares — an estimated $11K sold.

Meeder Asset Management first reported a position in EIGR in Q4 2016 and held it in 14 quarters. The position peaked at $13K in Q4 2019. 94 funds tracked by Wall St. Rank hold EIGR as of Q2 2020.

  • Meeder Asset Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 54 Eiger BioPharmaceuticals, Inc. shares in Q2 2020, an estimated $11K.
  • Meeder Asset Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2016 and held it in 14 quarters.
  • Meeder Asset Management's Eiger BioPharmaceuticals, Inc. position peaked at $13K in Q4 2019.
  • 94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.